Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats

Swiss pharmaceutical leader

(NOVN.SW) has updated its medium-term revenue outlook, , fueled by higher anticipated peak sales for its flagship oncology treatments Kisqali and Scemblix. This revised forecast, , signals the company’s optimism in its product lineup even as major drugs like Cosentyx and Entresto approach patent expiration. CEO Vas Narasimhan highlighted the robustness of Novartis’s development pipeline, which features eight lower-risk drugs each with peak sales potential between $3 billion and $10 billion, along with more than 30 promising candidates in advanced development.

Experts remain split on whether Novartis can maintain this growth trajectory. While

the company for reliably meeting its goals and raising its peak sales forecasts for Kisqali (now $10 billion) and Scemblix ($4 billion), J.P. Morgan pointed to challenges from patent cliffs and uncertainties in the drug pipeline after 2030. The bank will depend on strong clinical trial outcomes and regulatory green lights. Following the news, shares of gained 0.5%, .

Pre-market trading in the pharmaceutical industry was mixed.

after Abbott Laboratories announced plans to buy the liquid biopsy company for $105 per share. At the same time, Super Micro Computer (SMCI) rose over 5% after unveiling new GPU systems that use AMD’s Instinct MI355X chips.

Samsung Biologics, a contract development and manufacturing organization (CDMO) based in South Korea, is set for further expansion after spinning off its biosimilar business.

that this move could help attract additional CDMO deals by easing clients’ worries about their intellectual property being exposed to Samsung’s own drug development. According to the analyst, the change in the company’s valuation.

Novartis’s new outlook also highlighted the significance of its upcoming milestones. The company anticipates more than 15 pivotal readouts over the next two years,

. Still, for Kisqali in the U.S. could become an obstacle, especially if the drug is subject to Medicare price negotiations.